In a related commentary published in The New England Journal of Medicine, Satish K. Garg, MD, professor of medicine and pediatrics at the Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, and Sarit Polsky, MD, MPH, assistant professor of medicine and pediatrics at the Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, wrote that the trial revealed how a hybrid closed-loop system can be “safe and effective when customizable glucose targets within the pregnancy-specific target glucose range are used.” However, they said several questions were unanswered in the trial, including when hybrid closed-loop therapy should be initiated.